| 摘要 |
The present invention relates to a glucagon-like peptide (GLP) and immunoglobulin hybrid Fc fused polypeptide and, more specifically, to a fusion polypeptide having an increased half-life and an excellent effect compared with existing fusion polypeptides compared with existing fusion polypeptides, on the basis of the finding of immunoglobulin hybrid Fc suitable for GLP or an analog thereof, and to a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis and diarrhea caused by chemotherapy, or short-bowel syndrome, the composition containing the fusion polypeptide. The fusion polypeptide of the present invention has excellent resistance to DPP-4 enzyme while having an increased half-life compared with existing GLP-1 or GLP-2, thereby exhibiting excellent drug efficacy in the treatment of diabetes, inflammatory bowel disease, endoenteritis and diarrhea caused by chemotherapy, or short-bowel syndrome, compared with existing drugs, and thus the fusion polypeptide of the present invention can be usefully applied to medicine products. |
